ImetelChat

Hi Sargasso, there does seem to be a lot of pessimism as you note and the stock is in the basement. It is indisputable that there was some 12 week expectation that was not met although it may have been "approached". Clearly they are seeing something and want more time to evaluate. Knowing that multi...

The value of the recent update. So by telling us the MDS trial will extend into 2020 and thereby confirming the continuation of the trial I think we can do some numbers. If G has about 120 M in the bank just an estimate at this point (spending down to support studies) and no debt. They are assured o...

So to continue my thoughts on the updated MDS trial. (See previous note). As noted the study has been extended to 2019 top line and 2020 for completion. What does this tell us? Well for starters it is safe to surmise that enrollment will be resumed as planned in first half 2017. Since they only have...

CT site now shows update to MDS study. One German site has withdrawn. The study completion date has been pushed out to 2020!!! I guess the good news it that it is likely enrollment will be restarted next year. What is peculiar is that they did not take the opportunity to show the study as suspended ...

Fish, have posted a response on SA, if you think it is relevant please feel free to repost it here. Regards, bp

Fish, it's just an application not a grant. Curious though. bp

Fish, right you are, I stand corrected, thanks bp

Thanks Irish, I agree they should have plenty of data. Hoping we can see some of it at ASH. Fish Re DMC, the pilot study does not appear to have one but the Imbark and Imerge studies do. Go figure. bp

Fish, can you shed some light on what "line 1, line 2" type entries are and why the change? I can't find it anywhere. It is a seemingly small change that might just be record keeping, but reading a study should be transparent and straightforward but in this case (and others) it is certainly obscure....

Fish, the patents represent at least several hundred million invested with next to no return at the time of transfer. Perhaps recipients BTX/AST, provide some returns at some point. I am truly not qualified to try to answer your question. I am not a financial type but BTX now controls the IP for the...

Such a shame that so many of these beautiful patents were sold for next to nothing to btx. bp

You are right about the DMC--I wish they would stop the study already for efficacy in the face of an unmet medical need! bp

Fish, agreed, they should change the site and update it in a timely way. If I were a desperate patient surfing for a clinical trial I would be elated to find the study only to then find out it was really in a state of suspension re enrollment. The patients they recruited up until the update were pro...

Fish, I don't think the CT site now reflects the fact that these sites are no longer recruiting, even though the study. The site will probably be updated soon to reflect this consistent with Scarlett's update. bp

The pilot study has been updated Oct 5th in a seemingly innocuous way, just the addition of FDA on line 2. But why? This study has been on auto pilot for a while and Irish's husband has been forced to travel long distances for the drug that is basically available down the block. The pilot study has ...

Looks a little like VAC1/2 without the dendritic cell. The pursuit of solid tumors continues...bp

Nice find Fish, doubt presentation will be archived for our review but it would be wonderful for me to finally hear Sergei present. He has a very impressive CV. Wonder if Hoosier would be kind enough to review the other topics and comment as to whether the recent license to J and J implies some IP t...

More sites recruiting. Ruskies on board. bp

Thanks Fish, I missed that when I listened to the cc. bp

Fish, it could be as simple as spleen and symptoms. Just not enough yet. bp